Filing Details

Accession Number:
0001567619-23-005055
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-14 17:00:28
Reporting Period:
2023-03-10
Accepted Time:
2023-03-14 17:00:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080014 Innoviva Inc. INVA Pharmaceutical Preparations (2834) 943265960
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1813426 Pavel Raifeld 1350 Old Bayshore Highway, Suite 400
Burlingame CA 94010
Chief Executive Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-10 3,000 $10.87 9,799 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions in the open market at prices ranging from $10.865 to $10.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1 to this Form 4.
  2. Includes (1) 2,266 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 13, 2022, and (2) 3,000 shares of common stock acquired in multiple transactions in the open market on March 10, 2023, as described in greater detail in footnote 1 to this Form 4.